Jérôme Bouligand1,2, Clémentine Richard1,2,3, Dominique Valteau-Couanet4, Cedric Orear5, Lionel Mercier3, Romain Kessari6,7,8, Nicolas Simonnard6,7,8, Fabienne Munier6,7,8, Estelle Daudigeos-Dubus6,7,8, Bassim Tou1,2, Paule Opolon6,7,8, Alain Deroussent6,7,8, Angelo Paci9,10,11,12,13, Gilles Vassal6,7,8,14. 1. UMR S-1185, Faculté de Médecine Paris-Sud, Univ Paris-Sud, Université Paris Saclay, F-94276, Le Kremlin Bicêtre, France. 2. Laboratoire de Génétique moléculaire, Pharmacogénétique et Hormonologie, Hôpital Universitaire de Bicêtre, Assistance Publique Hôpitaux de Paris, F-94275, Le Kremlin-Bicêtre, France. 3. Service de Pharmacologie et d'Analyse du Médicament (SIPAM), Gustave Roussy Cancer Campus Grand Paris, Villejuif, 94805, France. 4. Department of Paediatric Oncology, Gustave Roussy Cancer Campus Grand Paris, Institut Gustave Roussy, Villejuif, 94805, France. 5. Integrated Biology Platform, Institut Gustave Roussy, Villejuif Cedex, France. 6. Laboratoire de Vectorologie et Thérapeutiques Anticancéreuses, Univ Paris-Sud, UMR 8203, Villejuif, 94805, France. 7. Laboratoire de Vectorologie et Thérapeutiques Anticancéreuses, Centre National de la Recherche Scientifique (CNRS), UMR 8203, Villejuif, 94805, France. 8. Laboratoire de Vectorologie et Thérapeutiques Anticancéreuses, Gustave Roussy Cancer Campus Grand Paris, UMR 8203, Villejuif, 94805, France. 9. Service de Pharmacologie et d'Analyse du Médicament (SIPAM), Gustave Roussy Cancer Campus Grand Paris, Villejuif, 94805, France. angelo.paci@gustaveroussy.fr. 10. Laboratoire de Vectorologie et Thérapeutiques Anticancéreuses, Univ Paris-Sud, UMR 8203, Villejuif, 94805, France. angelo.paci@gustaveroussy.fr. 11. Laboratoire de Vectorologie et Thérapeutiques Anticancéreuses, Centre National de la Recherche Scientifique (CNRS), UMR 8203, Villejuif, 94805, France. angelo.paci@gustaveroussy.fr. 12. Laboratoire de Vectorologie et Thérapeutiques Anticancéreuses, Gustave Roussy Cancer Campus Grand Paris, UMR 8203, Villejuif, 94805, France. angelo.paci@gustaveroussy.fr. 13. Pharmacology and Drug Analysis Department, Vectorology and Therapeutic Treatments, UMR CNRS 8203, 114 rue Edouard Vaillant, 94800, Villejuif, France. angelo.paci@gustaveroussy.fr. 14. Clinical Research Division, Institut Gustave Roussy, Villejuif Cedex, France.
Abstract
PURPOSE: Busulfan-melphalan high-dose chemotherapy followed by autologous stem cell transplantation is an essential consolidation treatment of high-risk neuroblastoma in children. Main treatment limitation is hepatic veno-occlusive disease, the most severe and frequent extra-hematological toxicity. This life threatening toxicity has been related to a drug interaction between busulfan and melphalan which might be increased by prior disturbance of iron homeostasis, i.e. an increased plasma ferritin level. METHODS: We performed an experimental study of busulfan and melphalan pharmacodynamic and pharmacokinetics in iron overloaded mice. RESULTS: Iron excess dramatically increased the toxicity of melphalan or busulfan melphalan combination in mice but it did not modify the clearance of either busulfan or melphalan. We show that prior busulfan treatment impairs the clearance of melphalan. This clearance alteration was exacerbated in iron overloaded mice demonstrating a pharmacokinetic interaction. Additionally, iron overload increased melphalan toxicity without altering its pharmacokinetics, suggesting a pharmacodynamic interaction between iron and melphalan. Based on iron homeostasis disturbance, we postulated that prior induction of ferritin, through Nrf2 activation after oxidative stress, may be associated with the alteration of melphalan metabolism. CONCLUSION: Iron overload increases melphalan and busulfan-melphalan toxicity through a pharmacodynamic interaction and reveals a pharmacokinetic drug interaction between busulfan and melphalan.
PURPOSE:Busulfan-melphalan high-dose chemotherapy followed by autologous stem cell transplantation is an essential consolidation treatment of high-risk neuroblastoma in children. Main treatment limitation is hepatic veno-occlusive disease, the most severe and frequent extra-hematological toxicity. This life threatening toxicity has been related to a drug interaction between busulfan and melphalan which might be increased by prior disturbance of iron homeostasis, i.e. an increased plasma ferritin level. METHODS: We performed an experimental study of busulfan and melphalan pharmacodynamic and pharmacokinetics in iron overloaded mice. RESULTS:Iron excess dramatically increased the toxicity of melphalan or busulfanmelphalan combination in mice but it did not modify the clearance of either busulfan or melphalan. We show that prior busulfan treatment impairs the clearance of melphalan. This clearance alteration was exacerbated in iron overloaded mice demonstrating a pharmacokinetic interaction. Additionally, iron overload increased melphalan toxicity without altering its pharmacokinetics, suggesting a pharmacodynamic interaction between iron and melphalan. Based on iron homeostasis disturbance, we postulated that prior induction of ferritin, through Nrf2 activation after oxidative stress, may be associated with the alteration of melphalan metabolism. CONCLUSION:Iron overload increases melphalan and busulfan-melphalan toxicity through a pharmacodynamic interaction and reveals a pharmacokinetic drug interaction between busulfan and melphalan.
Entities:
Keywords:
Nrf2; bone marrow transplantation; drug interaction; glutathione; metabolism; mice; pharmacodynamic; pharmacokinetics; toxicity
Authors: G Vassal; A Deroussent; D Challine; O Hartmann; S Koscielny; D Valteau-Couanet; J Lemerle; A Gouyette Journal: Blood Date: 1992-05-01 Impact factor: 22.113
Authors: L I Gordon; S G Brown; M S Tallman; A W Rademaker; S A Weitzman; H M Lazarus; C H Kelley; C Mangan; H Rubin; R M Fox Journal: Free Radic Biol Med Date: 1995-03 Impact factor: 7.376
Authors: A R Kallianpur; L D Hall; M Yadav; D W Byrne; T Speroff; R S Dittus; J L Haines; B W Christman; M L Summar Journal: Bone Marrow Transplant Date: 2005-06 Impact factor: 5.483
Authors: Jacqui M Marzec; Jason D Christie; Sekhar P Reddy; Anne E Jedlicka; Hue Vuong; Paul N Lanken; Richard Aplenc; Tae Yamamoto; Masayuki Yamamoto; Hye-Youn Cho; Steven R Kleeberger Journal: FASEB J Date: 2007-03-23 Impact factor: 5.191
Authors: J Bouligand; O Cabaret; M Canonico; C Verstuyft; L Dubert; L Becquemont; A Guiochon-Mantel; P Y Scarabin Journal: Clin Pharmacol Ther Date: 2010-11-24 Impact factor: 6.875
Authors: Jérôme Bouligand; Brigitte Delemer; Annie-Claude Hecart; Geri Meduri; Say Viengchareun; Larbi Amazit; Séverine Trabado; Bruno Fève; Anne Guiochon-Mantel; Jacques Young; Marc Lombès Journal: PLoS One Date: 2010-10-22 Impact factor: 3.240
Authors: A Cacchione; A LeMaitre; D Valteau Couanet; E Benhamou; L Amoroso; N Simonnard; O Hartmann Journal: Bone Marrow Transplant Date: 2008-06-30 Impact factor: 5.483
Authors: J Bouligand; A Le Maitre; D Valteau-Couanet; J Grill; L Drouard-Troalen; A Paci; O Hartmann; E Benhamou; G Vassal Journal: Clin Pharmacol Ther Date: 2007-03-28 Impact factor: 6.875
Authors: Alan L Myers; Jitesh D Kawedia; Richard E Champlin; Mark A Kramer; Yago Nieto; Romi Ghose; Borje S Andersson Journal: Expert Opin Drug Metab Toxicol Date: 2017-08-17 Impact factor: 4.481